https://fz.difbas.com/ 抗结核药物耳毒性、前庭损害、视神经损伤与前沿研究的信息雷达。 zh-CN Thu, 17 Sep 2026 06:10:17 +0000 https://pubmed.ncbi.nlm.nih.gov/42746387/ pubmed-42746387 Tue, 15 Sep 2026 08:00:00 +0800 BACKGROUND: All-oral shortened regimens for multidrug/rifampicin-resistant TB (MDR/RR-TB) commonly include cycloserine, which is associated with neuropsychiatric toxicity. Predictors of cycloserine-related adverse events remain poorly defined. We assessed whether baseline anaemia or hypoalbuminemia predict neuropsychi…（英文原文，待人工翻译复核） https://pubmed.ncbi.nlm.nih.gov/42746380/ pubmed-42746380 Tue, 15 Sep 2026 08:00:00 +0800 BACKGROUND: Clinical trials have demonstrated high efficacy of bedaquiline, pretomanid, and linezolid with or without moxifloxacin (BPaLM/BPaL) for rifampicin-resistant and multidrug-resistant TB (RR/MDR-TB), but real-world implementation data remain limited, particularly from South-East Asian programmatic settings. W…（英文原文，待人工翻译复核） https://pubmed.ncbi.nlm.nih.gov/42706201/ pubmed-42706201 Sat, 12 Sep 2026 08:00:00 +0800 Tuberculosis (TB) remains a major global public health problem. According to the World Health Organization (WHO) Global Tuberculosis Report 2025, an estimated 10.7 million people developed TB and approximately 1.23 million died from the disease in 2024. China continues to face a high burden of both TB and multidrug-re…（英文原文，待人工翻译复核） https://pubmed.ncbi.nlm.nih.gov/42721958/ pubmed-42721958 Thu, 10 Sep 2026 08:00:00 +0800 暂无摘要，请打开原文查看。（英文原文，待人工翻译复核） https://pubmed.ncbi.nlm.nih.gov/42722024/ pubmed-42722024 Thu, 10 Sep 2026 08:00:00 +0800 Age-related hearing loss (ARHL) is one of the most common chronic conditions in older age and is becoming an increasingly important topic in light of the demographic change. Despite existing effective diagnostic and technical treatment options, ARHL is often still insufficiently or inappropriately treated. The majorit…（英文原文，待人工翻译复核） https://pubmed.ncbi.nlm.nih.gov/42708833/ pubmed-42708833 Mon, 07 Sep 2026 08:00:00 +0800 BACKGROUND: Rituximab has changed the paradigm for management of pemphigus vulgaris (PV). Despite its widespread use, variability exists in its use, particularly related to dosing protocols, prophylaxis, and use in special populations. This study aimed to assess dermatologists' knowledge, attitude, and practices regar…（英文原文，待人工翻译复核） https://pubmed.ncbi.nlm.nih.gov/42704558/ pubmed-42704558 Mon, 07 Sep 2026 08:00:00 +0800 Isoniazid (INH), a first-line antibiotic for tuberculosis treatment, is known for its efficacy but also for its potential to cause neurotoxic side effects, which include peripheral neuropathy, seizures, and in rare cases, psychosis. This study aimed to evaluate the neurotoxic effects of INH on memory function and its…（英文原文，待人工翻译复核） https://pubmed.ncbi.nlm.nih.gov/42737781/ pubmed-42737781 Thu, 03 Sep 2026 08:00:00 +0800 Mutations in SLC26A4, which encodes the anion transporter pendrin, represent one of the most common genetic causes of hereditary hearing loss, including Pendred syndrome and DFNB4. Pendrin plays a critical role in maintaining ion homeostasis within the inner ear, particularly in the endolymphatic sac (ES), making it a…（英文原文，待人工翻译复核） https://pubmed.ncbi.nlm.nih.gov/42692809/ pubmed-42692809 Thu, 03 Sep 2026 08:00:00 +0800 INTRODUCTION: Rapid advances in whole-exome sequencing (WES) have enabled large-scale detection of pathogenic variants. Although hundreds of genes are implicated in hearing loss, up to half of inherited cases remain unsolved, limiting eligibility for gene therapy trials that require genetic diagnosis. Biobanks and ele…（英文原文，待人工翻译复核） https://pubmed.ncbi.nlm.nih.gov/42614031/ pubmed-42614031 Thu, 03 Sep 2026 08:00:00 +0800 PURPOSE OF REVIEW: Advances in genetic reprogramming and groundbreaking first-in-human gene therapy trials have generated significant momentum for treating sensorineural hearing loss. This review evaluates the expanding potential of biological approaches for hearing restoration. RECENT FINDINGS: The mammalian organ of…（英文原文，待人工翻译复核）